Who are ATV/r's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Reyataz + Norvir + Truvada, Reyataz + Epzicom, Lopinavir/r, Darunavir/Ritonavir (Prezista), PEP, Switch to DRV/cobicistat + 3TC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atv-r.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

ATV/r — Competitive Intelligence Brief

ATV/r (ATV/r) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor (boosted). Area: Infectious Disease.

marketed HIV protease inhibitor (boosted) HIV protease Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

ATV/r (ATV/r) — Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. ATV/r is a protease inhibitor boosted with ritonavir that blocks HIV protease, preventing viral replication by inhibiting the cleavage of viral polyproteins.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ATV/r TARGET	ATV/r	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	HIV protease inhibitor (boosted)	HIV protease
Reyataz + Norvir + Truvada	Reyataz + Norvir + Truvada	ViiV Healthcare	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Reyataz + Epzicom	Reyataz + Epzicom	ViiV Healthcare	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
Lopinavir/r	Lopinavir/r	Universidade Federal do Rio de Janeiro	marketed	Protease inhibitor	HIV protease
Darunavir/Ritonavir (Prezista)	Darunavir/Ritonavir (Prezista)	Kowa Research Institute, Inc.	marketed	HIV protease inhibitor	HIV protease
PEP	PEP	Christopher J. McLeod	marketed	Protease inhibitor	HIV protease
Switch to DRV/cobicistat + 3TC	Switch to DRV/cobicistat + 3TC	Hospitales Universitarios Virgen del Rocío	marketed	Antiretroviral combination therapy (protease inhibitor + pharmacokinetic booster + nucleoside reverse transcriptase inhibitor)	HIV protease, CYP3A4, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor (boosted) class)

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class
St Stephens Aids Trust · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ATV/r — Competitive Intelligence Brief. https://druglandscape.com/ci/atv-r. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab